110
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Intrapatient Development of Multi-Class Drug Resistance in an Individual Infected with HIV-1 CRF01_AE

, , &
Pages 3441-3448 | Published online: 25 Aug 2021

References

  • PalellaFJ, DelaneyKM, MoormanAC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. doi:10.1056/NEJM1998032633813019516219
  • SmithSJ, ZhaoXZ, PassosDO, LyumkisD, BurkeTR, HughesSH. Integrase strand transfer inhibitors are effective anti-HIV drugs. Viruses. 2021;13:205. doi:10.3390/v1302020533572956
  • ZaccarelliM, TozziV, LorenziniP, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. Aids. 2005;19:1081–1089. doi:10.1097/01.aids.0000174455.01369.ad15958840
  • ArmeniaD, Di CarloD, FlandreP, et al. HIV MDR is still a relevant issue despite its dramatic drop over the years. J Antimicrob Chemother. 2020;75:1301–1310. doi:10.1093/jac/dkz55431976521
  • FengY, HeX, HsiJH, et al. The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s. Aids. 2013;27:1793–1802. doi:10.1097/QAD.0b013e328360db2d23807275
  • PengX, WuH, PengX, JinC, WuN. Heterogeneous evolution of HIV-1 CRF01_AE in men who have sex with men (MSM) and other populations in China. PLoS One. 2015;10:e0143699. doi:10.1371/journal.pone.014369926623642
  • HuangA, HoganJW, LuoX, et al. Global comparison of drug resistance mutations after first-line antiretroviral therapy across human immunodeficiency virus-1 subtypes. Open Forum Infect Dis. 2016;3:ofv158. doi:10.1093/ofid/ofv15827419147
  • PengX, XuY, HuangY, ZhuB. Intrapatient evolutionary dynamics in an individual infected with HIV-1 CRF01_AE who experienced periods of treatment failure. AIDS Res Hum Retroviruses. 2021;37:139–146. doi:10.1089/aid.2020.021333191758
  • ZagordiO, BhattacharyaA, ErikssonN, BeerenwinkelN. ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data. BMC Bioinform. 2011;12:119. doi:10.1186/1471-2105-12-119
  • EdgarRC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinform. 2004;5:113. doi:10.1186/1471-2105-5-113
  • DarribaD, TaboadaGL, DoalloR, PosadaD. jModelTest 2: more models, new heuristics and parallel computing. Nat Methods. 2012;9:772. doi:10.1038/nmeth.2109
  • GuindonS, DufayardJF, LefortV, AnisimovaM, HordijkW, GascuelO. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59:307–321. doi:10.1093/sysbio/syq01020525638
  • DrummondAJ, SuchardMA, XieD, RambautA. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol. 2012;29:1969–1973. doi:10.1093/molbev/mss07522367748
  • MininVN, BloomquistEW, SuchardMA. Smooth skyride through a rough skyline: bayesian coalescent-based inference of population dynamics. Mol Biol Evol. 2008;25:1459–1471. doi:10.1093/molbev/msn09018408232
  • ShaferRW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51–8. doi:10.1086/50535616921473
  • GalliL, ParisiMR, PoliA, et al. Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO registry. Open Forum Infect Dis. 2020;7:ofaa456. doi:10.1093/ofid/ofaa45633241063
  • BessonGJ, LalamaCM, BoschRJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59:1312–1321. doi:10.1093/cid/ciu58525073894
  • van ZylG, BaleMJ, KearneyMF. HIV evolution and diversity in ART-treated patients. Retrovirology. 2018;15:14. doi:10.1186/s12977-018-0395-429378595
  • KamelianK, LepikKJ, ChauW, et al. Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis. Open Forum Infect Dis. 2019;6:ofz060. doi:10.1093/ofid/ofz06030895202
  • AnstettK, BrennerB, MespledeT, WainbergMA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14:36. doi:10.1186/s12977-017-0360-728583191
  • TsiangM, JonesGS, GoldsmithJ, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086–7097. doi:10.1128/AAC.01474-1627645238
  • ScullyEP, GandhiM, JohnstonR, et al. Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation. J Infect Dis. 2019;219:1084–1094. doi:10.1093/infdis/jiy61730371873
  • WangYM, DyerWB, WorkmanC, WangB, SullivanJS, SaksenaNK. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. Aids. 2000;14:2265–2272. doi:10.1097/00002030-200010200-0000711089614